Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Retained Earnings: 2020-2024

Historic Retained Earnings for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to -$462.9 million.

  • Mereo BioPharma Group's Retained Earnings fell 8.31% to -$493.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$493.7 million, marking a year-over-year decrease of 8.31%. This contributed to the annual value of -$462.9 million for FY2024, which is 10.31% down from last year.
  • According to the latest figures from FY2024, Mereo BioPharma Group's Retained Earnings is -$462.9 million, which was down 10.31% from -$419.6 million recorded in FY2023.
  • Mereo BioPharma Group's Retained Earnings' 5-year high stood at -$397.7 million during FY2020, with a 5-year trough of -$462.9 million in FY2024.
  • Its 3-year average for Retained Earnings is -$429.0 million, with a median of -$419.6 million in 2023.
  • Data for Mereo BioPharma Group's Retained Earnings shows a maximum YoY dropped of 10.31% (in 2024) over the last 5 years.
  • Over the past 5 years, Mereo BioPharma Group's Retained Earnings (Yearly) stood at -$397.7 million in 2020, then decreased by 0.66% to -$400.3 million in 2021, then dropped by 1.06% to -$404.6 million in 2022, then fell by 3.72% to -$419.6 million in 2023, then dropped by 10.31% to -$462.9 million in 2024.